Trump Pharma Tariffs

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

The proposed steep tariffs announced by the US on generic medicines could significantly affect India's largest pharmaceutical export market, economic think tank GTRI said on Wednesday. However, it said that the impact is unlikely to be uniform. "Many Indian generic medicines sell for seven to ten times less than branded alternatives. Even after a 100 per cent tariff, many products could remain cheaper than branded medicines, meaning much of the additional cost would likely be passed on to US healthcare providers, insurers and patients rather than immediately eliminating Indian exports," it said. It added that the greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable. "The proposed tariffs could significantly affect India's largest pharmaceutical export market," Global Trade Research Initiative (GTRI) founder Ajay Srivastava said, adding that India should also reduce

Donald Trump has proposed phased tariffs of up to 200% on imported generic drugs by 2028 to boost US manufacturing. Here's why the move matters for India's pharma sector and bilateral trade

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

The Trump administration last month proposed new tariffs of at least 10 per cent on 60 trading partners, citing what it said were lax forced-labor standards

Trump has seized on the cost of drugs as a key driver of affordability concerns ahead of the 2026 midterm elections